Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
| 対象疾患 | Degenerative Arthritis, Rheumatoid Arthritis, Traumatic Arthritis |
|---|---|
| 相 | 該当なし |
| スポンサー | Smith & Nephew, Inc. |
| ステータス | 早期終了 |
| 参加者数 | 65 名 |
| 介入（薬剤） | Implantation of Integra Cadence Total Ankle System |
| 開始日 | 2017年9月18日 |
| 完了日 | 2023年9月6日 |
| 結果公開日 | 2026年6月22日 |
概要
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)
Implant Survivorship at 2 Years
| Integra® Cadence™ Total Ankle System | 100 percentage of participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company